New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
04:55 EDTRHHBY, RHHBY, RHHBY, REPYY, REPYY, REPYYBarclays to hold a conference
Internationals Franchise Conference to be held in June 18-20.
News For RHHBY;REPYY From The Last 14 Days
Check below for free stories on RHHBY;REPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 29, 2014
16:40 EDTRHHBYStocks finish week higher after upbeat U.S. data reported
Subscribe for More Information
August 28, 2014
15:27 EDTREPYYRepsol eyes Talisman assets, no longer whole company, Bloomberg says
Subscribe for More Information
14:38 EDTREPYYRepsol no longer considering plans to buy all of Talisman Energy, Bloomberg says
Repsol (REPYY) is now targeting Talisman (TLM) shale assets and talks are moving slowly, according to Bloomberg.
09:16 EDTRHHBYPacific Biosciences milestone payment shows Roche commitment, says Maxim
Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.
09:01 EDTRHHBYPacific Biosciences discloses achievement of development milestone
Subscribe for More Information
08:21 EDTRHHBYRoche InterMune purchase could be big win if liver drug succeeds, Reuters says
Analysts have forecast annual sales of about $2B for InterMune's (ITMN) lung fibrosis treatment, pirfenidone, after it is approved, but success for the company's developmental drugs to treat similar damage to the liver and kidneys could be a "game-changer" for the company and its buyer, Roche (RHHBY), said Reuters. Reference Link
August 27, 2014
12:34 EDTREPYYTalisman Energy falling after reports that Repsol talks stalled
Shares of Canadian oil and gas producer Talisman Energy (TLM) are falling after media reports that talks between Spain's Repsol (REPYY), an integrated energy company, and Talisman are stalled. In late July, Talisman Energy said it has been approached about "various transactions" by Repsol. At the time, the company said in a press release, "Talisman acknowledges that it has been approached by Repsol with regards to various transactions. There is no assurance that any transaction will be agreed. Until such time as it is appropriate to make a public announcement on any potential transaction, Talisman does not intend to make any further comment on this matter." WHAT'S NEW: According to a Wall Street Journal report from last night, talks between Repsol and Talisman have stalled. According to the report, sources say that a possible deal is not dead but that the pace of the talks have "frozen." PRICE ACTION: Shares of Talisman Energy, which had rallied this summer after the news of Repsol's interest, are down 39c, or 3.6%, to $10.30 in midday trading, while Repsol shares are up fractionally to 25.11.
09:07 EDTRHHBYRoche unit granted FDA orphan status for hairy cell leukemia treatment
Subscribe for More Information
August 26, 2014
17:49 EDTREPYYRepsol, Talisman talks on oil and natural gas assets stall, WSJ says
Subscribe for More Information
17:15 EDTREPYYRepsol,Talisman talks on possible asset purchases slows, Dow Jones says
Repsol (REPYY) had been in discussions with Talisman (TLM) on possible asset purchases from Talisman but talks have slowed, says Dow Jones. Dow Jones added that the Talisman talks are not dead, but the pace of talks has "frozen."
August 25, 2014
16:13 EDTRHHBYOn The Fly: Closing Wrap
Stocks began the session in positive territory and proceeded to tack on gains throughout the morning. Despite a disappointing report on new home sales in July, the S&P surpassed the 2,000 level for the first time before noon. The market pared its gains shortly after the milestone was reached and drifted for the remainder of the session on light volume, as trading activity may be restrained all week ahead of the Labor Day weekend. ECONOMIC EVENTS: In the U.S., the Chicago Fed's National Activity index jumped to 0.39 in July from an upwardly revised 0.21 in June. Markit's preliminary August services PMI came in at 58.5, which was down from a prior reading of 60.8 but above the 58.0 consensus projection. New home sales dropped 2.4% to a 412K rate in July, missing expectations for them to have risen to a 430K annualized rate. COMPANY NEWS: Shares of InterMune (ITMN) surged $19.05, or 35.41%, to $72.85 after the company agreed to be acquired by Roche (RHHBY) for $74.00 per share in an all-cash transaction. The deal announcement comes less than two weeks after Bloomberg reported that Roche, along with big pharma peers Sanofi (SNY) and GlaxoSmithKline (GSK), had made takeover bids for the smaller drugmaker. A number of other biotech companies gained following the deal announcement, including bigger names like Gilead (GILD) and Celgene (CELG) and smaller ones such as Achillion Pharmaceuticals (ACHN) and Receptos (RCPT)... Burger King (BKW) shares rose $5.29, or 19.51%, to $32.40 after the company confirmed it is in talks regarding a potential strategic transaction with Canadian donut chain Tim Hortons (THI). Shares of Tim Horton's trading in New York also gained $11.88, or 18.91%, to $74.72 following the confirmation of news first reported by The Wall Street Journal. MAJOR MOVERS: Among the other notable gainers was Advaxis (ADXS), which advanced 75c, or 23.08%, to $4.00 after announcing it has entered into a clinical trial collaboration agreement with Merck (MRK). Also rising were shares of Comtech (CMTL), which jumped $1.70, or 4.84%, to $36.81 after Reuters said the company is working with Citigroup to explore a potential sale. Among the noteworthy losers was Chinese internet and software company Qihoo 360 Technology (QIHU), which fell $7.88, or 7.74%, to $93.87 despite reporting second quarter earnings and revenue that beat analysts' estimates. Also lower were shares of GrubHub (GRUB), which fell $3.60, or 8.42%, to $39.16 after filing to sell 10M shares of common stock. INDEXES: The Dow gained 75.65, or 0.44%, to 17,076.87, the Nasdaq rose 18.80, or 0.41%, to 4,557.35, and the S&P 500 advanced 9.54, or 0.48%, to 1,997.94.
12:19 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTRHHBYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
10:02 EDTRHHBYRoche unit launches PD-LI antibody
Spring Bioscience, a member of the Roche Group, announced the launch of its PD-L1 rabbit monoclonal immunohistochemistry antibody. This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 immunotherapy development program. The SP142 antibody is a component of the clinical trial assay designed by Ventana Medical Systems and used in early and late stage clinical trials for various tumor types including non-small cell lung cancer and urothelial bladder cancer. Internal comparison studies performed at Spring demonstrated that the PD-L1 antibody outperformed other commercially available PD-L1 antibodies.
09:11 EDTRHHBYOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTRHHBYRoche to hold a conference call
CEO Schwan and CFO Hippe discuss the acquisition of InterMune on a conference call to be held on August 25 at 9 am. Webcast Link
08:23 EDTRHHBYRoche acquisition makes sense, says Bernstein
Subscribe for More Information
07:11 EDTRHHBYInterMune volatility expected to move on Roche acquiring for $8.3B
Subscribe for More Information
August 24, 2014
20:27 EDTRHHBYRoche drops pursuit for remainder of Japan's Chugai, Bloomberg says
Subscribe for More Information
13:41 EDTRHHBYRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use